SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity

doi:10.21203/rs.3.rs-1962438/v1

Download PDF

Article

SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity

https://doi.org/10.21203/rs.3.rs-1962438/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

The ability to image adoptively transferred T cells in the body and to eliminate them to avoid toxicity will be vital for chimeric antigen receptor (CAR) T cell therapy, particularly against solid tumors with higher risk of off-tumor toxicity. Previously, we have demonstrated the utility of somatostatin receptor 2 (SSTR2) for CAR T cell imaging, illustrating the expansion and contraction of CAR T cells in tumor as well as off-tumor expansion. Using intercellular adhesion molecule 1-specific CAR T cells that secrete interleukin 12 (IL-12) as a model, herein we examined the potential of SSTR2 as a safety switch when combined with the SSTR2-specific maytansine-octreotate conjugate PEN-221. After rapid elimination of tumors, constitutive secretion of IL-12 led to continuous expansion of CAR T cells, causing systemic toxicity and elevated graft-versus-host disease (GvHD). Treatment with PEN-221 rapidly reduced the abundance of CAR T cells, decreasing the severity of toxicity and GvHD, and led to elongated survival. Our study supports the development of SSTR2 as a single genetic marker for CAR T cells that is readily applicable to humans both for anatomical detection of T cell distribution and an image-guided safety switch for rapid elimination of CAR T cells.

Autologous T cells modified to express chimeric antigen receptor (CAR) have shown a remarkable treatment efficacy against hematological cancers. So far four different CD19 specific CAR T cells have been approved against indications of diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), mantle cell lymphoma (MCL), and follicular lymphoma^1–4. More recently, two CAR T cells specific to B-cell maturation antigen (BCMA) have been approved to treat multiple myeloma^5,6. In comparison, the advances of CAR T cells against solid cancers have been less remarkable. The main challenges faced by CAR T cell therapy include the immunosuppressive features of the tumor microenvironment, antigen escape of the cancer cells, and the scarcity of tumor-specific antigens⁷. In addition, CAR T cell therapy could trigger toxicities, affecting both hematological and solid tumor cancers. These toxic effects range from mild to lethal, and include cytokine release syndrome (CRS), neurologic toxicity, and on-target off-tumor toxicity⁸.

Several approaches have been tested to avoid organ or systemic toxicity caused by CAR T cells. Some specifically address CRS and neurotoxicity, like the blockades of cytokines (GM-CSF, IL-1, IL-6) or catecholamines^9–11. Others, like dasatinib administration, affect all T cells of the organism by disrupting the signaling cascade downstream of CD3ζ and ZAP70¹².

For selective targeting of the CAR T cells, various engineered “off-switch” genes have been investigated. When the cells express one of these genes, an external molecule is introduced into patients to act as an antidote against the CAR T cells and therefore alleviate the provoked toxicities. Monoclonal antibodies (mAb) could be used against engineered epitopes, for example cetuximab against truncated epidermal growth factor receptor (tEGFR) or rituximab against CD20^13,14. Another approach is the expression of the enzymes by the CAR T cells that can convert innocuous compounds into toxic ones and therefore succumb to cell death. For instance, cells carrying herpes simplex virus type 1 thymidine kinase (HSV1-tk) that metabolize the nucleoside analog ganciclovir are killed by DNA damage after treatment with ganciclovir¹⁵. Similarly, cytosine deaminase allows CAR T cells to convert 5-fluorocytosine into highly toxic 5-fluorouracil, eliciting cell death¹⁶. An alternative approach is the introduction of inducible apoptotic genes, such as caspase-9 and Fas, that can induce cell death on the CAR T cells when expressed in the presence of a dimerizing agent such as rimiducid^17,18.

To accurately use the aforementioned strategies we require information about the CAR T cell distribution and activities related to associated toxicities. Systemic toxicity such as CRS caused by CAR T cells against hematological cancers can be readily predicted by detection of CAR T cells in circulation or blood markers such as IL-6, C-reactive protein, or IFN-γ¹⁹. However, in the setting of solid tumors, anatomical detection of CAR T cell location will be critical as the spatiotemporal expansion of CAR T cells can not be fully captured by traditional blood pharmacokinectic analyes. Several genetric markers, such as HSV1-tk²⁰, the human sodium-iodide symporter (hNIS)^21,22, the prostate-specific membrane antigen (PSMA)^23,24, and Escherichia coli dihydrofolate reductase enzyme (eDHFR)²⁵, have been explored for T cell imaging and potentially as a suicide switch. Among them, HSV1-tk has been translated to clinical use, wherein ¹⁸F-FHBG ([fluoro-3-(hydroxymethyl) butyl]guanine) for positron emission tomography (PET) imaging and ganciclovir for CAR T cell elimination^20,26−28. However, the viral nature of HSV-TK raises potential immunogenicity risks, and the tk specific radiotracers have substantial normal tissue uptake²⁹.

In this study, we propose somatostatin receptor 2 (SSTR2) as a dual genetic marker for imaging and elimination of CAR T cells. SSTR2 has physiologic expression restricted to neuroendocrine tissues, and is found to be overexpressed in some tumors including neuroendocrine, carcinoid, and small cell lung cancers^30,31. This expression pattern has provided an opportunity for imaging and killing these tumors by targeting SSTR2 with ⁶⁸Gallium and ¹⁷⁷Lutetium-conjugated octreotide peptide, respectively^32–34. Previously, we designed a single lentiviral vector for expression of CAR and SSTR2, and demonstrated the utility of SSTR2 as a genetic marker for anatomical detection of CAR T cell distribution in vivo³⁵. To further explore SSTR2 as a suicide gene and to seek alternative to ¹⁷⁷Lutetium radiotherapy (¹⁷⁷Lu-DOTATATE), we examined SSTR2-specific drug conjugate (the maytansine-octreotate conjugate PEN-221, Tarveda^36,37). PEN-221 is currently being evaluated for safety and efficacy against SSTR2-overexpressing advanced gastroenteropancreatic, lung, thymus, or other neuroendocrine tumors and against small cell lung cancer or large cell neuroendocrine carcinoma of the lung (ClinicalTrials.gov Identifier: NCT02936323).

To demonstrate the feasibility of SSTR2 as a dual genetic marker for both CAR T cell detection and suicide gene, we used a mouse model with human anaplastic thyroid carcinoma (ATC) xenograft and treated with intercellular adhesion molecule 1 (ICAM1)-specific CAR T cells that were designed to constitutively express SSTR2 and secrete IL-12. ICAM1 is overexpressed in a range of malignant cancers, including ATC, but is also expressed at lower levels in healthy cells like endothelial cells, immune cells, and some epithelial cells³⁸. This, together with the cross-reactivity of our CAR between human and mouse ICAM1, can closely approximate clinical on-target off-tumor toxicity³⁹. On the other hand, the constitutive secretion of the cytokine IL-12 would stimulate the growth and function of T cells, potentially increasing both the antitumoral effect and the related toxicities⁴⁰. The elevated proliferation and toxic effects of the CAR T cells in this model provide a valuable platform to test our ability to track in vivo and to eliminate these cells using the SSTR2 as a suicide gene.

PEN-221 induces dose-dependent SSTR2 internalization and specific cytotoxicity against SSTR2-expressing Jurkat T cells. SSTR2 belongs to the G-protein coupled receptor superfamily, and exhibits rapid internalization after binding its ligand, somatostatin⁴¹. To examine the activity of PEN-221 against SSTR2-expressing T cells, we transduced Jurkat T cells with a lentiviral vector to overexpress human SSTR2 receptor (Fig. 1a). Consistent with our previous observations of SSTR2 internalization induced by its agonists octreotide and lanreotide^35,39, PEN-221 stimulated dose-dependent internalization of SSTR2 receptor in Jurkat T cells, proving that octreotide-maytansine conjugate PEN-221 preserved the function of SSTR2 agonist (Fig. 1b,c). The internalization of PEN-221 receptor complex led to dose-dependent cellular cytotoxicity and inhibition of cell proliferation. SSTR2-expressing Jurkat T cells showed high sensitivity to PEN-221, with a nanomolar EC₅₀ (2.88 nM). Non-transduced Jurkat T cells that had no SSTR2 expression were much less susceptible to killing by PEN-221 with an EC₅₀ > 1 µM, indicating antigen specificity of the cytotoxic effect (Fig. 1d). These in vitro results demonstrated that PEN-221 triggers SSTR2 internalization and exerts cytotoxic effect that is dependent upon SSTR2 binding.

To further evaluate SSTR2-specific cytotoxicity of PEN-221 in vivo, we used a bilateral tumor model by subcutaneously implanting Jurkat-SSTR2 and Jurkat-NT cells into the opposite flanks of the same NSG-MHC-KO mice (Fig. 2a). Without PEN-221 treatment, Jurkat-SSTR2 and Jurkat-NT tumors showed progressive and comparable tumor growth, indicating that the expression of SSTR2 has no impact on cell growth (Fig. 2b,c). As anticipated, mice treated with PEN-221 after three doses exhibited nearly complete regression of the Jurkat-SSTR2 tumor. However, PEN-221 also stunted the growth of Jurkat tumors even without SSTR2 expression, which was particularly more apparent after five cycles of injections (Fig. 2b,c). The growth inhibition of SSTR2-negative Jurkat tumors should be due to non-specific uptake of PEN-221, similar to what was seen with the killing of Jurkat-NT cells in vitro at higher concentrations of PEN-221 (Fig. 1d). Overall, more drastic elimination of Jurkat-SSTR2 tumors in vivo and a 1,000-fold higher potency of PEN-221 against SSTR2-positive Jurkat cells were consistent with prior studies that examined the specificity of PEN-221 against SSTR2³⁷.

PEN-221 treatment mitigates CAR T-associated toxicity in vivo and extends survival. In order to assess the cytotoxic effect of PEN-221 against CAR T cells in vivo and its potential to reduce the related toxicities, we established a mouse ATC model and used the 2nd generation ICAM1-specific micromolar affinity CAR (F292A-4-1BB-3ζ⁴²) T cells that co-express human SSTR2 and human IL-12 (Fig. 3a,b). ATC subcutaneous tumors were generated by the inoculation of Fluc-expressing 8505C cells into the upper left flank of NSG and NSG-MHC-KO mice (Fig. 3c)⁴³. The immunocompromised NSG mice and the mouse strain with additional MHC class I and class II deficiency (NSG-MHC-KO) provide models useful to distinguish between xenogeneic GvHD and on-target off-tumor toxicity. GvHD occurs when the T cell receptor (TCR) from grafted T cells (human CAR T cells in our model) recognize antigens presented by MHC on the host’s healthy tissues. Since these NSG-MHC-KO mice are resistant to GvHD, only the more clinically relevant CAR-mediated on-target off-tumor toxicities would be observed in this model.

CAR T cells were intravenously injected five days after the tumor implantation. The positive effects of controlling the tumor growth were seen by bioluminescence imaging one week later, with almost complete remission after two weeks in both mouse strains (Fig. 3d–f). In order to mimic the emergency clinical scenario where toxicity emerges rapidly, we delayed PEN-221 treatment until 20 days after CAR T cell infusion when severe toxicity began to occur, characterized by weight loss, ruffled fur, and lethargy. All 5 NSG mice without PEN-221 required euthanasia within 25 days after CAR T cell administration, while all NSG-MHC-KO mice were alive and healthy. The death of CAR T-treated NSG mice without PEN-221 was due to CAR T toxicity as the tumor had been already completely eliminated within 7 days of CAR T cell infusion. In comparison, NSG mice without CAR T cell treatment exhibited progressive growth of tumors, yet survivied beyond 40 days. The NSG mice that were treated with PEN-221 rapidly recovered from severe GvHD toxicity, and the majority (4 out of 5) survived during PEN-221 treatment. However, mice began showing GvHD symptoms soon after the termination of PEN-221 treatment, and eventually all succumbed to death. This indicated that five cycles of PEN-221 treatment over two weeks was still insufficient to completely eliminate CAR T cells (Fig. 3d and g). In contrast to severe GvHD in NSG mice, GvHD associated symptoms were totally absent in NSG-MHC-KO mice and no survival differences were observed between CAR T cell cohorts with or without PEN-221 treatment (Fig. 3g).

PEN-221 treatment eliminates CAR T cells in vivo. Distribution and expansion of CAR T cells in vivo were monitored weekly by PET/CT imaging (Fig. 4). Rapid localization of CAR T cells at tumor sites was observed 8 days after CAR T cell infusion, which was followed by systemic expansion by 14 days after CAR T cell infusion. PET/CT imaging performed 2 days after PEN-221 (day 22) clearly indicated rapid yet incomplete elimination of CAR T cells in lungs, liver, and lymph nodes. After four more cycles of PEN-221, further reduction of CAR T cells was apparent (day 35) and the majority of CAR T cells expanded in lungs and liver were eliminated. In comparison, in mice without PEN-221 CAR T cells continued to expand in the major organs (lungs, liver, spleen) and in circulation (Fig. 4a,b). We also noted significant discrepancy in the rate of CAR T elimination in lungs compared to that in site of tumor growth. In contrast to significant reduction of CAR T cell abundance in the lungs after a single administration of PEN-221 (day 22), CAR T cell density at the tumor site continued to increase before eventually subsiding after five cycles of PEN-221 (day 35) (Fig. 4c,d). In NSG mice, CAR T cells bounced back after termination of PEN-221 treatment, leading to relapse of GvHD symptoms and eventual death. By contrast, CAR T cell density in NSG-MHC-KO strain remained low after the withdrawal of the drug, in both tumors and lungs (Fig. 4). These results indicate that CAR T cell recurrence seen in NSG strain was to a great extent due to TCR-MHC driven T cell stimulation. No correlation between the presence of CAR T cells and GvHD associated symptoms or survival was found on NSG-MHC-KO mice.

Serum cytokines reflect expansion and killing of CAR T and tumor cells. The kinetics of serum cytokines closely corroborates the CAR T cell dynamics observed by PET/CT (Fig. 5). IL-12, IFN-γ, and perforin levels in blood increased during the first week after CAR T cell infusion. These levels droped markedly during PEN-221 treatment but remained high in untreated mice. After PEN-221 withdrawal, IFN-γ and perforin levels rose rapidly back to pre PEN-221 levels in NSG mice, while IL-12 more gradually increased back to pre PEN-221 levels. In comparison, the levels of IL-12, IFN-γ, and perforin in NSG-MHC-KO strain slowly rose after PEN-221 withdrawal and stayed at significantly lower levels. IL-6 and IL-8 cytokines were found to be directly secreted by tumor cells, and closely reflected tumor growth and killing. Consistent with complete tumor elimination by 2-weeks of CAR T cell infusion with no sign of relapse, IL-6 and IL-8 stayed at undetectable levels in CAR T cohorts with or without PEN-221 treatment, whereas these continued to rise in mice without CAR T cell treatment. Serum levels of IL-2 and TNF-𝛼 were below the quantification limit.

In this study we demonstrated the feasibility of SSTR2 as a genetic marker that couples a safety switch for CAR T cell ablation with an imaging reporter for PET. CAR T cell treatments have become a promising therapy for hematological cancers with six different treatments already approved by the FDA^1–5. Safety is still one of the biggest concerns for the translation to clinic due to CAR T cell related toxicities, like life-threatening CRS or on-target off-tumor toxicities⁸. In recent years, numerous approaches have been taken to develop CAR T cell therapies that avoid these adverse events while keeping their therapeutic efficacy⁴⁴. Among them, the inclusion of suicide switches that allow specific ablation of CAR T cells in case of undesirable effects could be crucial for an efficient and safe application of this therapy in the clinic.

We chose SSTR2 as a suicide switch based on its limited expression in healthy tissues^30,31, the availability of a specific cytotoxic drug conjugate^33,36, and our previous results using it as an imaging marker for detection of CAR T cell distribution in vivo³⁵. In addition, two radiotracers (⁶⁸Ga-DOTATATE, ⁶⁴Cu-DOTATATE) have been approved for human use, and other alternatives (e.g., ⁶⁸Ga-DOTATOC, ¹⁸F-NOTA-Octreotide) that are widely available provide comparable imaging sensitivity and specificity. SSTR2 could potentially be used as a suicide switch using the FDA-approved radiotherapy (¹⁷⁷Lu-DOTATATE⁴⁵) or investigational SSTR2-specific drug conjugate PEN-221³⁶. PEN-221 is a conjugate consisting of maytansine, a potent microtubule-targeted cytotoxic agent, conjugated with the somatostatin analog Tyr3-octreotate. PEN-221 delivers its cytotoxic activity through internalization triggered by specific binding to surface SSTR2 in cells and binding to tubulin³⁷. PEN-221 has proved effective when targeting tumor cells and is being evaluated for clincal safety and efficacy against cancers that express SSTR2^37,46.

In our current work, we demonstrated the ability to use PEN-221 to eliminate SSTR2-expressing CAR T cells both in vitro and in vivo. In vitro, Jurkat cells transduced to express SSTR2 showed high sensitivity to PEN-221 treatment at nanomolar concentration. In vivo, biweekly intravenous injections of PEN-221 were enough to eliminate much of CAR T cells and their activity, as confirmed by both PET imaging and cytokine analysis. Efficient elimination of systemically expanded CAR T cells by PEN-221 led to drastic elongation of survival of NSG mice, a timing of PEN-221 intervention chosen after the onset of systemic toxicity. After the withdrawl of PEN-221 treatment, CAR T cells rebounded in NSG strain, recovering to the pre-PEN-221 treatment levels at ~ 10 days after the final PEN-221 injection. This was driven profoundly by the activation signals between TCR and MHC as such rebound was not evident in NSG strain with MHC knockout. In comparison to immediate elimination of systemically expanded CAR T cells even after a single administration of PEN-221, T cell elimination at the tumor site was much slower and clear reduction was seen only after 2–3 rounds of PEN-221. The discrepancy of T cell susceptibility to PEN-221 at off-tumor versus tumor site is likely to be caused by the difference of PEN-221 distribution, which may be more limited within and in the vicinity of the tumor sites with less developed blood vessels. More immediate distribution of PEN-221 into well perfused organs may be advantageous to rapidly eliminate CAR T cells expanding at the major organs and off-tumor sites while allowing slower elimination of CAR T cells localized within the solid tumors.

Interestingly, different immunocompromised mouse strains showed very diverse toxicity effects in response of CAR T cells. While NSG mice suffered clear symptoms of GvHD, pronounced as weight loss, ruffled fur, and lethargy, NSG-MHC-KO mice survived despite comparable expansion of CAR T cells. The stark difference in toxicity between the two strains with or without MHC expression provided evidence that the severe toxicity observed in NSG mouse model was largely due to xenogeneic reaction, i.e., human TCR recognition of mouse peptide/MHC, rather than CAR recognition of murine antigens expressed in mouse tissues. The prolonged survial of NSG-MHC-KO mice was in line with observations with genome-edited CAR T cells deficient in expression of TCR, which prevented the incidence of xenogeneic GvHD⁴⁷. The lack of toxicity in MHC deficient NSG strain further supported our previous observation that affinity-tuned CAR against ICAM1 avoided reaction with ICAM1 expressed in mouse tissues despite its cross-reaction between human and murine ICAM1^39,48.

The main advantage of our system is the ability to use the same marker for both an imaging probe and a suicide switch. Without a reliable imaging method, we can only depend on indirect measures of the CAR T cell presence, such as cytokine evaluation or analysis of circulating T cells. These methods are inadequate for solid tumors and do not give us spatiotemporal information of the CAR T cell distribution. Being able to evaluate the proliferation and biodistribution of the CAR T cells in vivo would give us the opportunity to address the potential toxicity problems before the appearance of symptoms, as well as to monitor the response to treatment. This would allow us to optimize the CAR T cell modulation or ablation, developing personalized treatments to avoid toxicities without compromising the antitumoral effect. However, CAR T cell reponse to PEN-221 treatment may differ from the tumors naturally overexpressing SSTR2. Furthermore, a clinical use of PEN-221 to eliminate CAR T cells may differ from the dose-response determined from the ongoing trials against SSTR2 positive cancer patients (NCT02936323). Finding an optimal dose of PEN-221 to be used as a safety switch for CAR T cells will significantly be aided by spatiotemporal mapping of CAR T cells in patients by PET/CT. Recently, HSV1-tk have been proposed as a dual marker for CAR T cell imaging and elimination²⁸. In this system ganciclovir can be used as an elimination agent, killing the cells that express the enzyme by DNA damage. The dependence on interfering DNA/RNA synthesis and consequently slower cell death could be a downside. Also, the viral origin of HSV-TK could be a major obstacle due to the immunogenicity reported in human studies²⁹. On the other hand, FHBG, the imaging probe used for PET-based imaging, is not approved for human use nor as is widely available as SSTR2-specific radiotracers.

Overall, our study presents proof-of-principle evidence for the use of SSTR2 as a dual marker for CAR T cell imaging and elimination. Both the imaging probe specific to SSTR2 and the elimination agent, PEN-221, have been clinically approved or being tested, which makes this method ready to translate to the clinic. Our system offers a widely applicable strategy for treatment of different cancers that could lead to more efficient and safe CAR T cell therapies.

Cell lines. The human thyroid cancer cell line 8505C was obtained from Sigma in 2018; HEK 293T and Jurkat T cell lines were purchased from the American Type Culture Collection (ATCC) in 2019. 8505C and Jurkat T cell lines were cultured in RPMI-1640 (Corning) supplemented with 10% heat-inactivated fetal bovine serum (FBS); HEK 293T cell line was cultured in Dulbecco's Modified Eagle's Medium (DMEM, Corning) supplemented with 10% FBS. 8505C and Jurkat T cell lines were stably transduced with a Firefly Luciferase-F2A-GFP (FLuc-GFP) lentivirus (Biosettia) for in vivo assessment of tumor burden in mouse models. All cell lines were maintained at 37°C in a 5% CO₂ atmosphere and were routinely validated to be Mycoplasma free using a MycoAlert™ detection kit (Lonza).

Vector construction. The CAR construct contained from the 5′-LTR end: a c-Myc tag, a micromolar affinity inserted (I) domain (F292A) derived from lymphocyte function-associated antigen (LFA1) for ICAM1 targeting, a CD8 hinge and transmembrane domain, a 4-1BB costimulatory domain and a CD3ζ signaling domain. The genetic marker SSTR2 and stimulatory cytokine IL-12 were introduced at the C-terminus of the CAR using a porcine teschovirus-1 2A (P2A) and a Thosea asigna virus 2A (T2A) ribosome-skipping sequence to obtain comparable expression of CAR, SSTR2 and IL-12. This tricistronic construct was then cloned into a third-generation lentiviral vector backbone under the control of EF1α promotor. A construct containing only SSTR2 was also generated and cloned into the same lentiviral backbone.

Recombinant lentivirus production and T cell transduction. Lentivirus was produced by transient transfection of HEK 293T cells with LV-MAX™ lentiviral packaging mix (Thermo Fisher) and corresponding transfer plasmid using Lipofectamine™ 3000 transfection reagent (Thermo Fisher). The media were replaced with Opti-MEM I Reduced Serum Media (Gibco) 6 h post-transfection. The lentiviral supernatant was harvested 48 h post-transfection and concentrated with Amicon ultra centrifugal filter units (Millipore). Jurkat T cells were transduced by resuspending 1 × 10⁵ cells in 200 µl medium containing 8 µl virus supernatant. The culture medium was refreshed after 24h incubation, and the cells were incubated for an additional 48 h before use. Primary T cell transduction was performed as described previously⁴⁹. Briefly, CD4⁺ and CD8⁺ T cells were enriched from human leukopaks of healthy donors (Biological Specialty Corporation) and activated with human T-activator CD3/CD28 Dynabeads (Gibco) at a 1:1 bead to cell ratio and cultured in complete T cell growth medium (TexMACS medium (Miltenyi Biotec) supplemented with 5% human AB serum (Sigma), 12.5 ng/mL IL-7 (Miltenyi Biotec), and 12.5 ng/mL IL-15 (Miltenyi Biotec)). T cells were transduced twice with lentivirus (1:25 dilution) at 24 and 48 h after activation, followed by expansion in 50 ml bioreactor tubes (TubeSpin, TPP) at 1 − 3 × 10⁶ cells/ml on a tube roller (Thermo Fisher) with a setting of 5 rpm. T cell products were harvested when 100-folds T cell expansion was achieved, typically on day 9 or 10, and cryopreserved in a 1:2 mixture of T cell complete growth medium and CS10 (STEMCELL) for in vitro and in vivo experiments.

Flow cytometric analysis. To assess cell-surface expression of CAR and SSTR2, transduced cells were stained with FITC anti-c-myc antibody (Miltenyi Biotec, clone SH1-26E7.1.3) and APC anti-human SSTR2 antibody (R&D systems, clone 402038). T lymphocytes and sub-populations were identified using a cocktail of anti-human PE-Cy5 CD3, anti-human PE CD4 and anti-human FITC CD8 antibodies (Biolegend, clone UCHT1; RPA-T4; RPA-T8). Live cells were selected using calcein blue (Sigma-Aldrich) staining along with forward- and side-scatter gating. Flow cytometry was performed on a Gallios flow cytometer (Beckman Coulter, Inc.) and analyzed with FlowJo software (Tree Star, Inc.).

In vitro cytotoxicity and internalization assay. The SSTR2-expressing Jurkat T cells and non-transduced Jurkat T cells (NT) were plated in 96 well at a density of 1 × 10⁵ cells/well and treated with 10-folds serially diluted PEN-221 (a kind gift from Tarveda Therapeutics) starting at a dose of 1 µM. After 4 h PEN-221 treatment, cells were washed three times and resuspended in fresh medium. The plate was further incubated at 37°C in a 5% CO₂ atmosphere up to 72 h. After 72 h of incubation, cells were analyzed by flow cytometry after staining with APC anti-human SSTR2 antibody (R&D systems, clone 402038) and calcein blue (Sigma-Aldrich). Calcein blue negative cells was determined to be dead target cells. The percentage of cytotoxicity was calculated using the equation: %Cytotoxicity = 100 × (experimental death – spontaneous death)/(100 – spontaneous death), where spontaneous death represents cell death from the control group (0.5% DMSO). To evaluate SSTR2 internalization induced by PEN-221, the mean fluorescence intensity (MFI) of SSTR2 was determined for each treatment condition. EC₅₀ curves for cytotoxicity and SSTR2 internalization were generated using the nonlinear regression analysis with GraphPad Prism 9. Each experiment was performed in triplicate.

In vivo mouse studies. Male mice between 5 to 7-week-old were purchased from the Jackson Laboratory and housed in the Animal Core Facility at Weill Cornell Medicine. Two different strains were used: NOD-scid IL2Rg^null (NSG, stock no. 005557) and NSG-B2M^null (IA IE)^null (NSG-MHC-KO, stock no. 030547). All the procedures conducted on mice were approved by the Weill Cornell Medicine Institutional Animal Care and Use Committee (Protocol number: 2012–0063) and were consistent with the recommendations of the American Veterinary Medical Association and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All studies are reported in accordance with ARRIVE guidelines. To assess the specificity of PEN-221 to SSTR2 in vivo, we established a bilateral tumor model by subcutaneously implanting 1 × 10⁶ Jurkat-SSTR2 cells in the left flank and 1 × 10⁶ Jurkat-NT cells in the right flank. Thirty-five days after tumor inoculation, mice were treated with PEN-221 (25 µg in 100 µl water with 0.5% DMSO) every 3–4 days via tail vein or left untreated. Subcutaneous ATC tumor models were established by injecting 1 × 10⁶ FLuc-expressing 8505C tumor cells into the left flank. CAR T cells (10 × 10⁶ cells/mouse) were injected intravenously 5 days after the xenograft. PEN-221 (25 µg/mouse) were administered every 3–4 days via tail vein between 20 and 33 days following T cell administration (5 injections total). Jurkat T and 8505C cells were prepared in 1:1 mixture of medium and Matrigel (Corning) for implantation, whereas CAR T cells were injected via tail vein freshly after thawing. Tumor growth was monitored weekly via bioluminescence imaging using IVIS Spectrum in vivo imaging system (PerkinElmer). Images were acquired 10 minutes after intraperitoneal injection of 200 µL of 15 mg/mL D-luciferin (GoldBio) and analyzed using Living Image Software (PerkinElmer). Whole-body bioluminescensce flux (photons/s) was used to estimate tumor burden. Tumors were measured weekly with a caliper and tumor volumes were estimated using the formula V = (length × width²)/2. Proliferation and biodistribution of CAR T cells were monitored weekly by PET/CT imaging using an Inveon micro-PET/CT scanner (Siemens Medical Solutions). The radiotracer ¹⁸F-NOTA-Octreotide (ABX Pharmaceuticals) was prepared as previously described⁴² and injected intravenously around 2 h before the imaging. A reference of 100 µL of 10%ID/cm³ was included for quantification. PET/CT images were processed with Amide v1.0.5 and Inveon Research Workplace software, including ROIs of the lungs and tumors to study CAR T cell expansion. Retro-orbital blood collection was performed weekly and serum cytokines were analyzed by a LEGENDplex™ kit (Biolegend) according to the manufacturer’s instructions. Animals reaching the humane endpoint (e.g., > 25% body weight loss, signs of illness or distress including ruffled fur, difficulty with diet, or abnormal posture) were euthanized and all deaths recorded for survival analysis.

Statistics

Statistical analysis was performed using GraphPad Prism 9 software. An unpaired, two-tailed student’s t-test or a two-way ANOVA with Tukey’s multiple comparisons test was performed to evaluate differences between groups. Mouse survival was analyzed by a log-rank (Mantel-Cox) test. All data are represented as mean ± SD. P < 0.05 was considered statistically significant.

Data availability

All data generated or analyzed during this study are included in this published article.

Acknowledgments

This work was supported by NIH grants R01-CA254035 and R01-CA217059, and institutional grant (MI3, Weill Cornell Medicine). The authors would like to acknowledge Tarveda Therapeutics Inc. for kindly providing PEN-221 and the Citigroup Biomedical Imaging Center at Weill Cornell Medicine for technical assistance.

Authors’ Contributions

Y.A., Y.Y., and M.M.J. designed and planned the studies. Y.A., Y.Y., Y.V., and J.E.M. conducted experiments and acquired data. Y.A. and Y.Y. analyzed data. M.M.J. provided rescources. Y.A., Y.Y., and M.M.J. wrote the manuscript. All authors reviewed the manuscript. The co–first authorship order was assigned by last name alphabet.

Competing interests

The authors declare no competing interests.

Schuster, S. J. et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 377, 2545–2554 (2017).
Neelapu, S. S. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377, 2531–2544 (2017).
Wang, M. et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 382, 1331–1342 (2020).
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
Raje, N. et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 380, 1726–1737 (2019).
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).
Junghans, R. P. The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. Cancer Gene Ther 24, 89–99 (2017).
Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321–3330 (2016).
Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697–709 (2019).
Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24, 739–748 (2018).
Staedtke, V. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564, 273–277 (2018).
Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med 11, eaau5907 (2019).
Paszkiewicz, P. J. et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest 126, 4262–4272 (2016).
Serafini, M. et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 15, 63–76 (2004).
Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719–1724 (1997).
Tiraby, M. et al. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 167, 41–49 (1998).
Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365, 1673–1683 (2011).
Thomis, D. C. et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97, 1249–1257 (2001).
Murthy, H., Iqbal, M., Chavez, J. C. & Kharfan-Dabaja, M. A. Cytokine Release Syndrome: Current Perspectives. Immunotargets Ther 8, 43–52 (2019).
Keu, K. V. et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med 9 (2017).
Emami-Shahri, N. et al. Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Nat Commun 9, 1081 (2018).
Sakemura, R. et al. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. Cancer Immunol Res 9, 1035–1046 (2021).
Castanares, M. A. et al. Evaluation of prostate-specific membrane antigen as an imaging reporter. J Nucl Med 55, 805–811 (2014).
Minn, I. et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci Adv 5, eaaw5096 (2019).
Sellmyer, M. A. et al. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. Mol Ther 28, 42–51 (2020).
Yaghoubi, S. et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med 42, 1225–1234 (2001).
Fillat, C., Carrio, M., Cascante, A. & Sangro, B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 3, 13–26 (2003).
Murty, S. et al. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res 80, 4731–4740 (2020).
Berger, C., Flowers, M. E., Warren, E. H. & Riddell, S. R. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107, 2294–2302 (2006).
Yamada, Y. et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 89, 251–255 (1992).
de Herder, W. W., Hofland, L. J., van der Lely, A. J. & Lamberts, S. W. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10, 451–458 (2003).
Zhang, H. et al. Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC. J Nucl Med 52, 123–131 (2011).
Garkavij, M. et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer 116, 1084–1092 (2010).
Wulfert, S. et al. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Mol Imaging Biol 16, 586–594 (2014).
Vedvyas, Y. et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight 1, e90064 (2016).
White, B. H. et al. Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo. J Med Chem 62, 2708–2719 (2019).
Whalen, K. A. et al. Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. Molecular Cancer Therapeutics 18, 1926–1936 (2019).
Dustin, M. L., Rothlein, R., Bhan, A. K., Dinarello, C. A. & Springer, T. A. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137, 245–254 (1986).
Vedvyas, Y. et al. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep 9, 10634 (2019).
Chmielewski, M. & Abken, H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother 61, 1269–1277 (2012).
Patel, Y. C. Somatostatin and its receptor family. Front Neuroendocrinol 20, 157–198 (1999).
Park, S. et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep 7, 14366 (2017).
Min, I. M. et al. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors. Clin Cancer Res 23, 7569–7583 (2017).
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17, 147–167 (2020).
Das, S., Al-Toubah, T., El-Haddad, G. & Strosberg, J. (177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 13, 1023–1031 (2019).
Halperin, D. M. et al. The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results. J Clin Oncol 39, 4110–4110 (2021).
Poirot, L. et al. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Cancer Res 75, 3853–3864 (2015).
Shimaoka, M. et al. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc Natl Acad Sci U S A 98, 6009–6014 (2001).
Yang, Y. et al. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses. Cancer Immunol Res 9, 1158–1174 (2021).

No competing interests reported.

Download PDF

Editorial decision: Major revision
28 Sep, 2022
Reviews received at journal
25 Sep, 2022
Reviewers agreed at journal
18 Sep, 2022
Reviewers invited by journal
18 Sep, 2022
Editor assigned by journal
18 Sep, 2022
Editor invited by journal
17 Aug, 2022
Submission checks completed at journal
17 Aug, 2022
First submitted to journal
14 Aug, 2022

You are reading this latest preprint version

SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity

Status:

Version 1

Abstract

Figures

Introduction

Results

Discussion

Materials And Methods

Statistics

Declarations

References

Additional Declarations

Status:

Version 1